Yinghong Gao

Venture Partner, Viva BioInnovator

Yinghong Gao (Yinghong Gao | LinkedIn; Yinghong Gao | Google Scholar) is a Venture Partner of Viva BioInnovator. She is responsible for the post investment management of multiple VBI portfolio companies. She is also heavily involved in deal sourcing and spearheading collaborations with external institutions and investment communities in the innovative drug discovery space. Prior to that she has extensive drug R&D and BD/licensing experience working with Neurocrine Biosciences, Arena Pharmaceticals, Merck KGaA and other biotech companies. She has contributed to the discovery of Neurocrine's GnRH antagonist ORILISSA® and Arena’s S1P modulator Etrasimod.

Yinghong Gao
Amacathera Logo

AmacaThera is a clinical-stage biotechnology company transforming therapeutics to make a difference in patient health. Our unique, injectable hydrogel platform provides localized, sustained drug delivery to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer and other hard‑to‑reach target areas.

Contact Us

MaRS Centre, West Tower,
661 University Ave Suite 1300,
Toronto, ON M5G 0B7

[email protected]